Where is MiniMed located?

MiniMed is headquartered in Northridge, United States.

How many employees does MiniMed have?

As of May 31, 2026, the latest employee count at MiniMed is 97677.

Where does MiniMed rank among its competitors?

MiniMed ranks 14th amongst 64 active competitors, of which 13 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was CeQur, which secured $100M in Jun, 2026.

Who are the top competitors of MiniMed?

MiniMed's top competitors include Tandem Diabetes, Insulet and Ypsomed. Among them, CeQur secured the most recent funding round in June, 2026.

MiniMed - 2026 Company Profile, Funding & Competitors

MiniMed is a public company based in Northridge (United States), founded in 1993. It operates as an Innovative diabetes management solutions: insulin pumps, smart pens, and continuous glucose monitoring. The company has 64 active competitors, including 13 funded and 17 that have exited. Its top competitors include companies like Tandem Diabetes, Insulet and Ypsomed.

Company Details

Innovative diabetes management solutions: insulin pumps, smart pens, and continuous glucose monitoring. They offer advanced systems for automated insulin delivery, continuous glucose monitoring, and smart multiple daily injection therapy. Their products aim to simplify diabetes care, reduce the burden of management, and improve the lives of people with diabetes. They provide a range of resources, including product support, training programs, and community forums. They are committed to providing extraordinary experiences for their customers, offering support and education to help individuals manage their diabetes effectively. They focus on innovation, aiming to develop intuitive solutions that integrate seamlessly into daily life. Their offerings include insulin pump systems, smart insulin pens, injection ports, and therapy management software. They also provide financial support programs and resources for healthcare professionals.

Key Metrics

Founded Year

1993

Location

Northridge, United States

Stage

Public

Investors

Investor Growth Capital & 1 more

Ranked

14^th among 64 active competitors

Employee Count

97,677 as on May 31, 2026

Similar Companies

Insulet & 38 more

Exit Details

Public

View MiniMed's full profile

MiniMed got listed on Mar 06, 2026.

Click here to take a look at MiniMed's IPO in detail

MiniMed is a funded company. MiniMed has 2 institutional investors.

View details of MiniMed's funding rounds and investors

MiniMed's employee count trend

MiniMed has 97,677 employees as of May 26. Here is MiniMed's employee count trend over the years:

Uncover MiniMed's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MiniMed include Tandem Diabetes, Insulet and Ypsomed. Here is the list of Top 10 competitors of MiniMed, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tandem Diabetes 2008, San Diego (United States), Public	Developer of devices for continuous glucose monitoring and manual insulin delivery	$101M	Gynther Capital, Domain Associates & 5 others	77/100
2nd	Insulet 2000, Boston (United States), Public	Manufacturer of wearable, tubeless insulin delivery systems for diabetes management	$120M	Federated Hermes, Piper Jaffray & 13 others	74/100
3rd	Ypsomed 2003, Burgdorf (Switzerland), Acquired	Developer of self delivery injection systems and diabetes care systems	$7.45M	BV Partners, BV Group	64/100
4th	Kaleido 2013, Utrecht (Netherlands), Series D	Developer of insulin therapy for treating diabetes	$183M	Life Sciences Partners, Innovation Industries ... & 10 others	64/100
5th	CeQur 2008, Horw (Switzerland), Series E	Developer of wearable insulin delivery patch	$492M	Endeavour Vision, Schroders & 7 others	59/100
6th	Microtech Medical 2011, Hangzhou (China), Public	Medical devices developer for diabetes care	$88.2M	Tencent, IDG Capital & 9 others	57/100
7th	Sigrid Therapeutics 2014, Stockholm (Sweden), Series C	Developer of therapies to treat metabolic and chronic lifestyle diseases	$27M	Irrus Investments, Joyance Partners & 9 others	57/100
8th	Omnipod 1999, Acton (United States), Unfunded	Provider of smart wearable disposable pod provides insulin delivery	-	-	54/100
9th	Embecta 2022, Parsippany (United States), Public	Manufacturer of insulin delivery solutions, including pen needles and insulin syringes	-	-	53/100
10th	Modular Medical 2017, San Diego (United States), Series A	Developer of insulin pump for insulin delivery	$5.28M	-	52/100
14th	MiniMed 1993, Northridge (United States), Public	Innovative diabetes management solutions: insulin pumps, smart pens, and continuous glucose monitoring	-	Investor Growth Capital, Galen Partners	45/100